




PHARMACEUTICAL 2021

PROVECTUS BIOPHARMACEUTICALS INC. Rank 379 of 402





PHARMACEUTICAL 2021

PROVECTUS BIOPHARMACEUTICALS INC. Rank 379 of 402

The relative strengths and weaknesses of PROVECTUS BIOPHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PROVECTUS BIOPHARMACEUTICALS INC. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 166% points. The greatest weakness of PROVECTUS BIOPHARMACEUTICALS INC. is the variable Assets, Current, reducing the Economic Capital Ratio by 212% points.

The company's Economic Capital Ratio, given in the ranking table, is -374%, being 421% points below the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	424
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	30,712
Liabilities, Non-Current	45
Other Assets	121
Other Compr. Net Income	-10
Other Expenses	0
Other Liabilities	39
Other Net Income	-1,714
Other Revenues	0
Property and Equipment	45
Research and Development	2,813
Selling, General and Administrative Expense	2,151

Output Variable	Value in 1000 USD
Assets	589
Liabilities	30,796
Expenses	4,964
Revenues	0
Stockholders Equity	-30,206
Net Income	-6,678
Comprehensive Net Income	-6,683
Economic Capital Ratio	-374%